$1.39
0.0554.14%
Last update: Jul 13, 2:43 PM
MaxCyte Inc Stock Guidance
MXCTNASDAQ
MaxCyte (MXCT) last issued guidance on May 12, 2026 for fiscal year 2026. The company guided revenue in the range of $30.00M - $32.00M for the period.
Compared to prior guidance, MaxCyte maintained its revenue forecast from a prior range of $30.00M - $32.00M.
MaxCyte has issued 25 guidance updates between March 6, 2023 and May 12, 2026. During this period, the company raised its outlook 6 times and lowered it 12 times, providing investors with insight into management's evolving expectations.
Latest Guidance Date
May 12, 2026
Guidance Period
Full Year 2026
Revenue Guidance Range
$30.00M - $32.00M
MaxCyte Guidance History
Review all historical guidance issued by MaxCyte, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for MaxCyte (MXCT)?
The most recent guidance for MaxCyte (MXCT) was reported on May 12, 2026 for the fiscal year 2026. MaxCyte forecasted revenue between $30.00M and $32.00M for the period.
What revenue range did MaxCyte (MXCT) guide for?
MaxCyte (MXCT) guided revenue in the range of $30.00M to $32.00M for the fiscal year 2026.
Did MaxCyte (MXCT) raise or lower guidance?
MaxCyte (MXCT) maintained its revenue guidance from a prior range of $30.00M - $32.00M to $30.00M - $32.00M for the fiscal year 2026.
When did MaxCyte (MXCT) last issue guidance?
MaxCyte (MXCT) last issued guidance on May 12, 2026 for the fiscal year 2026.
